Ocular Therapeutix, Inc.

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

Anyone who thought that US approval at the second time of asking for UCB S.A. 's Bimzelx was a mere formality will have read the Food and Drug Administration's latest facility inspection report with